Dissertation
Dissertation > Medicine, health > Oncology > Gastrointestinal Cancer > Gastric neoplasms

Predict Effect of Response and Survival of Polymorphisms of XPD, XPA, XRCC1 and GSTP1 in Patients with Advanced Gastric Cancer Treated with Oxaliplatin Based Chemotherapy

Author LiuTongXin
Tutor XiongJianPing
School Nanchang University
Course Oncology
Keywords Gene polymorphism Advanced gastric cancer Oxaliplatin Chemotherapy
CLC R735.2
Type Master's thesis
Year 2011
Downloads 29
Quotes 0
Download Dissertation

Objective: This study investigated the peripheral blood of patients with advanced gastric cancer XPD Lys751Gln, XPA A23G of XRCC1 of Arg399Gln, GSTPlIle105Val gene polymorphisms with oxaliplatin-based chemotherapy efficacy and lifetime of the relationship. Methods: 110 cases diagnosed with advanced gastric cancer and accept the peripheral blood of patients with oxaliplatin-based chemotherapy, the use of the method of analysis and gene sequencing of the PCR-PFLP all patients with XPD Lys751Gln, XPA A23G of XRCC1 of Arg399Gln GSTP1Ile105Val gene polymorphism. Evaluate the efficacy of 2 chemotherapy cycles according to RECIST criteria and statistical chemotherapy, progression-free survival (mPFS) and overall survival period (MST). Analyze the relationship of the different genotypes of each gene and the efficacy of chemotherapy and survival. Results: 1,110 patients with advanced gastric cancer patients with chemotherapy effective rate of 49.1%, mPFS128 days, MST 308 days. XPD Lys751Gln, XPA A23G of Arg399Gln of XRCC1 GSTPllle105Val gene genetic subtype distribution are in line with the Hardy-Weinberg law. Chemotherapy efficiency and XRCC1 of Arg399Gln the GSTPlIle105Val gene polymorphism has nothing to do with the XPD Lys751Gln, XPA A23G gene polymorphism. XRCC1 Arg399Gln Arg / Arg Arg / Gln Gln / Gln type efficient statistical difference (62.1% VS 27.9%, X2 = 12.201, P lt; 0.001); of GSTP1 Il105Val Ile / Ile and Ile / Val Val / Val compared to an efficient statistical difference (35.7% vs. 71.2%, X2 = 13.052, P lt; 0.001). 4, no disease progression-free survival (mPFS) gene polymorphisms XRCC1 Arg399Gln, GSTPlIle105Val has nothing to do with the XPD Lys751Gln, XPA A23G gene polymorphism. XRCC1 of Arg399Gln Arg / Arg, Arg / Gln Gln / Gln type, mPFS a statistically significant difference (VS 84 days in 140 days, X2 = 13.801, P lt; 0.001); of GSTP1 Ile105Val Ile / Ile and Ile / Val Val / Val compared mPFS significant statistical difference VS 150 days (90 days, X2 = 18.579, P lt; 0.001). 5, the overall survival time (MST) of Arg399Gln of XRCC1, GSTP1Ile105Val genetic polymorphisms, and XPD Lys751Gln, XPA A23G gene polymorphism unrelated. XRCC1 Arg399Gln Arg / Arg Arg / Gln Gln / Gln type, MST there is a statistically significant difference (330 days VS.210 days, X2 = 21.249, P lt; 0.001); of GSTP1 Ile105Val Ile / Ile type Ile / Val Val / Val compared, MST, a statistically significant difference (228 days VS 356 days, X2 = 21.555, P lt; 0.001). 6 gene polymorphism joint analysis found 0 risk gene group, a risk gene group, two risk gene set of the three groups of patients mPFS, there are significant with difference X2 = 28.508, P lt; 0.001; and the three groups of patients carried two the two comparison: the 0 risk genome and compared to a risk genomic X2 = 15.967, P lt; 0.001, both with significant difference; a 0 risk genome and compared to two risk genomic X2 = 25.076, P lt; 0.001, both statistically differences; a risk genome and two risk genomic X2 = 3.741, P = 0.053, no statistically significant difference between the two. Correction using Cox hazard regression model, the 0 risk genotype as a reference, can be found mPFS with a (P lt; 0.001) or 2 (P = 0.0037) risk genes. 7,3 group of patients MST significant difference X2 = 40.311, P lt; 0.001; and the three groups were conducted pairwise comparisons: 0 risk gene group a risk gene group, X2 = 16.142, P lt; 0.001; the 0 risk gene groups, and the two risk gene group X2 = 40.046, P lt; 0.001; 1 risk gene group and two risk gene groups compared, X2 = 9.150, P = 0.002, both have have statistically significant difference. Correction and Cox hazard regression model, 0 risk genotypes as a reference, and can be found in the MST shorter with a (P lt; 0.001) or 2 (P = 0.001) risk genes. Conclusion: of XRCC1 of Arg399Gln, GSTPlIle105Val gene polymorphism with advanced gastric cancer patients with oxaliplatin-based chemotherapy chemotherapy efficiency and survival-related gene polymorphisms joint detection and a better prediction of survival.

Related Dissertations
More Dissertations